已经开发了通过使用H 2 O-THF中的NaOH亲核取代3-芳基-4-硝基呋喃烷中的硝基来制备待探索的3-芳基-4-羟基呋喃烷的通用而简单的方法。用各种甲基化试剂(CH 2 N 2,MeI,(MeO)2 SO 2)研究了3-芳基-4-羟基呋喃恶烷的甲基化,这首次表明3-芳基-4-羟基呋喃恶烷倾向于侧-链质变互变异构。在温和条件下,合成了新型呋喃喃衍生物,N(5)-烷基化产物(3-芳基-5-甲基-1,2,5-恶二唑-4(2 H)-一2-氧化物)。与O的区域选择性形成-烷基化产物(3-芳基-4-甲氧基呋喃烷)。
[EN] PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE<br/>[FR] PTÉRIDINONES EN TANT QU'INHIBITEURS DE POLO-LIKE KINASE
申请人:ELAN PHARM INC
公开号:WO2011079114A1
公开(公告)日:2011-06-30
The present invention provides compounds having a structure according to Formula (I) or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
A novel and efficient catalytic system including TEMPO/acetaldoxime/InCl3 for aerobic oxidation of primary amines to oximes
作者:Jiatao Yu、Xiaohua Cao、Ming Lu
DOI:10.1016/j.tetlet.2014.08.083
日期:2014.10
simple and efficient catalytic system including TEMPO/acetaldoxime/InCl3 for aerobicoxidation of primaryamines to corresponding oximes by using toluene as the solvent is described. This practical method can use O2 as the economic and green oxidant, tolerate a wide range of substrates, which can afford the target oximes in moderate to excellent yields.
The present invention relates to compounds of formula I:
or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.
The present invention provides compounds having a structure according to Formula (I):
or a salt or solvate thereof, wherein ring A, E
1
, E
2
, R
1
, R
2
, R
3
and R
4
are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
The present invention provides compounds having a structure according to Formula (I):
or a salt or solvate thereof, wherein ring A, U
1
, U
2
, U
3
, R
2
, R
3
and R
4
are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.